iBio, Inc.
IBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -50% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -189% | 100% | – | 100% |
| R&D Expenses | $4 | $3 | $2 | $2 |
| G&A Expenses | $3 | $2 | $3 | $3 |
| SG&A Expenses | $3 | $2 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $5 | $5 | $5 |
| Operating Income | -$6 | -$5 | -$5 | -$4 |
| % Margin | -5,951% | -2,599% | – | -2,209.5% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$6 | -$5 | -$5 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$5 | -$5 | -$4 |
| % Margin | -5,720% | -2,581.5% | – | -2,182% |
| EPS | -0.11 | -0.31 | -0.49 | -0.48 |
| % Growth | 64.5% | 36.7% | -2.1% | – |
| EPS Diluted | -0.11 | -0.31 | -0.49 | -0.48 |
| Weighted Avg Shares Out | 53 | 16 | 10 | 9 |
| Weighted Avg Shares Out Dil | 53 | 16 | 10 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$5 | -$5 | -$4 |
| % Margin | -5,395% | -2,417% | – | -2,013% |